Losartan in Adolescents (Ages 12 to 17): Transitioning to Adult Care

Why the Transition Period Is High-Risk for Adolescents on Losartan

Adolescents on long-term losartan face a statistically well-documented drop in care continuity at age 18. A 2018 analysis published in the Journal of the American Heart Association found that young adults with hypertension were significantly less likely to receive ongoing antihypertensive prescriptions in the 12 months after leaving pediatric care compared with matched adult patients already established in adult practice [1]. That gap matters because losartan works through sustained angiotensin II receptor blockade: missed doses allow blood pressure to rebound, proteinuria to worsen, and in patients with Marfan syndrome, aortic root growth to accelerate.

What Changes Clinically at Age 18

Pediatric cardiologists, nephrologists, and general pediatricians all have age-based panels. When a patient turns 18, the referring relationship ends, insurance coverage may change, and the adult provider receiving the patient may never have managed a young person with Marfan syndrome or a congenital solitary kidney. The clinical history, growth-chart context, and prior echocardiography data often do not transfer automatically.

The American Academy of Pediatrics (AAP) states in its "Supporting the Health Care Transition from Adolescence to Adulthood in the Medical Home" policy: "Transition planning is a process, not an event, and should begin no later than age 14." [2] That principle applies directly to adolescents on losartan, where stopping the drug abruptly or delaying the first adult-care appointment by even three to six months can have measurable hemodynamic consequences.

The Numbers Behind Medication Gaps

A 2020 cohort study in Pediatrics (N=1,247 adolescents with chronic kidney disease) found that 48% of patients had at least one 30-day gap in renin-angiotensin-aldosterone system (RAAS) blocker coverage in the 24 months after transition, compared with 19% in the 24 months before transition [3]. Those gaps were independently associated with a 1.4-fold increase in proteinuria at two years post-transfer. Losartan is the most commonly prescribed ARB in this age group because of its established pediatric dosing data and its oral suspension availability for younger patients who carry their prescription into adolescence.

Losartan Dosing: Pediatric Parameters That Carry Into Adult Practice

Adult providers accustomed to starting losartan at 50 mg once daily in a 60-year-old with essential hypertension may not realize that an 18-year-old arriving from a pediatric nephrologist could be on a weight-based dose that looks different. Getting this right at the first adult visit prevents either under-treating the patient or alarming them with a prescription change they do not understand.

FDA-Approved Dosing Framework for Ages 6 to 17

The FDA label for losartan potassium (Cozaar, Merck) specifies the following for pediatric hypertension:

• Starting dose: 0.7 mg/kg once daily, up to 50 mg total
• Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is lower
• The oral suspension (2.5 mg/mL) is used for patients who cannot swallow tablets; most 12 to 17-year-olds transition to tablets [4]

By age 16 to 17, many adolescents are at or near adult weight, meaning their weight-based ceiling aligns with the standard adult dose of 50 to 100 mg/day. The adult provider should confirm the patient's current dose, compare it against current body weight, and document whether the dose was set for blood pressure control, proteinuria reduction, or aortic-root surveillance. Each of those goals has a different blood pressure target.

Indication-Specific Blood Pressure Targets

| Indication | BP Target (Adolescent/Young Adult) | Guideline Source | |---|---|---| | Primary hypertension | <130/80 mmHg | AHA/ACC 2017 [5] | | CKD with proteinuria | <130/80 mmHg | KDIGO 2021 [6] | | Marfan syndrome | <130/80 mmHg; some experts target <120/80 | AHA/ACC Marfan 2022 [7] |

Adult providers should not reflexively switch a well-controlled patient to a different ARB or ACE inhibitor simply because losartan is "the pediatric drug." Formulary substitutions mid-transition are a documented cause of confusion and non-adherence.

Monitoring Requirements Before and After Handoff

Losartan requires regular laboratory surveillance. Pediatric practices often run these labs as part of routine well-child or subspecialty visits. Adult primary care does not have that built-in rhythm, so explicit instructions must be in the transfer summary.

Core Lab Panel

At minimum, every adolescent transferring on losartan needs these labs checked within 30 days of the first adult visit:

1. Basic metabolic panel (serum creatinine, BUN, potassium, sodium)
2. Urine albumin-to-creatinine ratio (uACR) or urine protein-to-creatinine ratio (uPCR) if nephropathy is the indication
3. Complete blood count if the patient is also on a diuretic
4. Fasting lipid panel, given the high rate of metabolic comorbidity in this demographic

The National Kidney Foundation's KDIGO 2021 guideline recommends monitoring serum creatinine and potassium at least every three to six months in patients on RAAS blockade with CKD stages G3, G4 [6]. Adolescents aging into the adult CKD system often arrive with years of stable eGFR data; that data should be scanned and summarized, not simply listed in a 40-page PDF.

Echocardiography for Marfan Syndrome

For the subset of adolescents on losartan for Marfan syndrome, the transition summary must specify the most recent aortic root Z-score and the absolute diameter. The COMPARE trial (N=233, published in The Lancet in 2013) compared losartan with atenolol in patients with Marfan syndrome and showed that losartan reduced aortic root growth rate to 0.77 mm/year versus 1.35 mm/year with atenolol (P<0.001) [8]. That trial included participants as young as early adulthood; the pediatric data that followed suggested similar directional benefit. The adult cardiologist needs to know the patient's baseline diameter, not just their current prescription.

Blood Pressure Measurement at Transition

Home blood pressure monitoring (HBPM) data collected in the months before transfer gives the adult provider a real-world average that a single office reading cannot. The 2022 AAP clinical practice guideline on pediatric hypertension supports using HBPM as a supplement to ambulatory blood pressure monitoring (ABPM) in adolescents [9]. Providing 30 days of HBPM logs in the transfer summary reduces the chance of the adult provider ordering a full hypertension workup unnecessarily.

Reproductive Health Counseling: Non-Negotiable Before Transfer

Losartan carries FDA Pregnancy Category D labeling for second and third trimester exposure and a Black Box Warning: use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus [4]. Adolescent females approaching adulthood must receive explicit counseling about this risk before leaving pediatric care.

What the Counseling Must Cover

• Losartan must be stopped as soon as pregnancy is confirmed, ideally before conception is attempted
• The patient needs a clear plan: which provider to call, what to switch to (usually methyldopa or labetalol during pregnancy), and how quickly
• Reliable contraception should be discussed annually for any female patient of reproductive age on losartan
• Male patients do not face direct fetal risk, but should still understand why their partners' providers need to know about this medication

The ACOG Practice Bulletin on Chronic Hypertension in Pregnancy (updated 2019) explicitly lists ARBs including losartan as contraindicated in pregnancy and recommends switching to a safe alternative before conception whenever possible [10]. A pediatric provider handing off a 17-year-old female on losartan without this conversation is leaving a preventable risk in place.

Contraception and Adherence as a Combined Conversation

Combining the contraception talk with a broader adherence conversation improves uptake. Adolescents who understand the "why" behind their medication are measurably more adherent. A 2019 meta-analysis in JAMA Pediatrics covering 47 studies (N=14,820 adolescents with chronic disease) found that motivational interviewing combined with written transition materials increased medication adherence rates by 21 percentage points versus standard care at 12-month follow-up [11].

Building the Transition Plan: A Step-by-Step Protocol

The following framework synthesizes AAP, AHA, and nephrology society guidance into a concrete checklist for pediatric providers managing adolescents on losartan. Adult receiving providers should request this documentation explicitly if it does not arrive with the referral.

Step 1 (Age 14 to 15): Start the Conversation

• Introduce the concept of transition at a routine visit. Use the AAP/Got Transition "Health Care Transition" readiness assessment tool.
• Document the indication for losartan in plain language the patient can repeat back.
• Confirm the patient can name their medication, dose, and why they take it.
• Begin building a portable medical summary (one to two pages maximum).

Step 2 (Age 16 to 17): Prepare the Transfer Package

The transfer package should include:

1. Current losartan dose and the indication (hypertension, nephropathy, Marfan syndrome, or combination)
2. All blood pressure readings from the past 12 months, including any ABPM or HBPM logs
3. Most recent labs (BMP, uACR or uPCR, lipids)
4. Echocardiography report and aortic root measurements if applicable
5. Growth chart context (weight and height trend, relevant for weight-based dosing history)
6. Allergies, prior medication trials, and reasons for switching to losartan
7. Pregnancy counseling documentation for female patients
8. Contact information for the specialist who will continue subspecialty care (nephrology, cardiology)

Step 3 (Age 17.5 to 18): Confirm the Receiving Provider

A handoff is not complete until an adult provider accepts the patient. The pediatric team should:

• Identify a specific adult PCP or internist by name, not just a practice group
• Confirm the first appointment is scheduled before the last pediatric visit
• Send the transfer package at least 30 days before the final pediatric appointment
• Offer a "bridge call" between the pediatric specialist and adult specialist when the case is complex (aortic root dilation exceeding 4.0 cm, eGFR below 45 mL/min/1.73m2, or difficult-to-control blood pressure on three or more agents)

Step 4 (First 6 Months in Adult Care): Active Follow-Through

• Adult provider confirms labs within 30 days (see Core Lab Panel above)
• Blood pressure target reviewed against indication-specific guidelines
• Prescription continuity confirmed: same drug, same dose, same pharmacy
• If formulary substitution is necessary, a direct ARB-to-ARB switch with equivalent dosing should be used, not an automatic class switch to an ACE inhibitor without clinical review

Special Populations Within the Adolescent Losartan Group

Not all adolescents on losartan are the same. Three subgroups deserve specific attention at transition.

Adolescents with CKD and Heavy Proteinuria

CKD in adolescents transitions to adult nephrology, a specialty with different staffing ratios and recall systems. The ESCAPE trial (N=397 children, published in NEJM in 2009) showed that intensified blood pressure control targeting the 50th percentile using RAAS blockade, primarily with ramipril but with design principles applicable to losartan, slowed progression to renal replacement therapy compared with conventional control [12]. The adolescent arriving in adult nephrology from a pediatric practice may have benefited from this intensified strategy for years. An adult nephrologist who relaxes the BP target to <140/90 because that is the standard adult CKD threshold would be treating a different goal than the one that preserved this patient's renal function through childhood.

Adolescents with Marfan Syndrome

These patients typically follow with pediatric cardiology until age 18, then transfer to adult congenital heart disease (ACHD) programs or adult cardiologists with connective tissue disorder experience. The handoff should include the most recent aortic imaging (preferably MRI or CT with measurements at the annulus, sinuses of Valsalva, sinotubular junction, and ascending aorta). Losartan dose adjustments in this population are driven by aortic root growth rate, not blood pressure alone.

Adolescents with Type 2 Diabetes and Hypertension

This group is growing. The ADA's 2024 Standards of Care in Diabetes recommends RAAS blockade as first-line therapy for diabetic nephropathy in patients with persistent albuminuria, with a target blood pressure of <130/80 mmHg [13]. An adolescent arriving in adult endocrinology or internal medicine from a pediatric diabetes center may already be on both metformin and losartan. Confirming that both medications remain active at transfer, with no unintentional gap in either, requires a system-level check at the receiving adult practice.

What Adult Providers Need to Know About Adolescent Losartan Patients

Adult internists and family medicine physicians are not always trained in the nuances of pediatric-to-adult handoff. A few points reduce the most common errors.

Do Not Assume the Dose Is Wrong

An 18-year-old on 50 mg losartan daily is not under-dosed by adult standards. An 18-year-old who weighs 45 kg and is on 25 mg daily may also be correctly dosed by weight. Check before changing.

Hyperkalemia Risk in CKD Transition Patients

Adolescents with CKD on losartan may be using sodium bicarbonate, phosphate binders, or dietary potassium restriction. Altering any one of those variables changes the hyperkalemia risk. Get a baseline potassium before any dose adjustment. The FDA label for losartan specifically warns that potassium supplements or potassium-sparing diuretics should be used with caution in patients on ARBs [4].

The First Visit Sets the Tone

Research on adolescent adherence consistently shows that the first adult-care visit predicts long-term retention. A patient who leaves that visit feeling heard, not lectured, and with a clear plan is more likely to refill their prescription. Reviewing the transfer summary before the visit, not during it, signals competence and builds trust.